ClinicalTrials.gg
Active, not recruitingNCT07413991Updated Aug 13, 2026

Expressive Writing Program Among Young Adults With Blood Cancer

An interventional study of Expressive Writing Workshop in Hematologic Malignancy, sponsored by Blood Cancer United. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Blood Cancer United · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Planned enrollment
149th of 660
100 · median 40
Started
2026
with 39 others
No phase
139 of 823
38 open now
Primary completion
2026-08
later than 64 of 274 live
Registered
809th of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 149th largest by planned enrollment of the 660 interventional ones that give a count, is one of 40 that started in 2026, is one of 139 with no phase, reaches primary completion later than 64 of the 274 other live ones, and was the 809th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness.

Participants will

  • Take part in an online expressive writing workshop for four weeks
  • Take three surveys at different times over 12 weeks Researchers will compare changes in mental wellness reported by the participants of the workshop to those who will wait four weeks to start the workshop. After four weeks, the participants who are waiting will start their workshop.
Read the detailed description

The goal of this study is to learn more about an expressive writing workshop among people with blood cancer. The main question it aims to answer is whether and how an expressive writing workshop can impact mental wellness.

Participants will

  • Take part in an online expressive writing workshop for four weeks
  • Take three surveys at different times over 12 weeks Participants will be randomly assigned to one of two study groups by chance. Group 1 will start the workshop the following week. Group 2 will wait 4 weeks before starting the workshop. The workshop is the same for both groups. Each week, participants will be given a writing prompt and asked to spend at least 15 minutes writing a response. They will be able to share their writing response in a private online community group if they would like, but sharing is not required.

Researchers will then compare changes in mental wellness between group 1 and 2.

03

Conditions studied

  • Hematologic Malignancy

Keywords

  • expressive writing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a hematologic diagnosis in treatment or after treatment is completed, who is currently between the ages of 18 and 39 (young adult), or the informal caregiver of a young adult blood cancer patient
  • Located within the U.S., Canada, or U.S. territories
  • Able to read and write in English

Exclusion criteria

Exclusion Criteria:

  • Located outside of the U.S., Canada, or its territories
  • Participant is a minor aged 17 years or below
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Group 1

    Primary Intervention Group

    Behavioral: Expressive Writing Workshop

  • Placebo comparator
    Group 2

    Wait List Control Group

    Behavioral: Expressive Writing Workshop

Interventions

  • BehavioralExpressive Writing Workshop

    Group 1 will start the workshop the following week. Group 2 will wait 4 weeks before starting the workshop. There is an equal chance of being placed group 1 or group 2. You cannot choose your study group. The workshop is the same for both groups.

06

What researchers measure

Primary outcomes

  1. Mental Wellbeing

    Participants' mental wellbeing will be evaluated using the Warwick Edinburgh Mental Wellbeing Scale (WEMWBS), specifically the original 14-item scale developed by researchers at the University of Warwick and the University of Edinburgh in 2007. This self-report questionnaire asks questions about participants' feelings and how they have been functioning over the last two weeks to capture a comprehensive view of their recent mental wellbeing. Participants will rate each question on a 5-point Likert scale, and their responses will be totaled to a mental wellbeing score ranging from 14-70; higher scores indicate greater wellbeing.

    Time frame: Baseline, 4, and 8 weeks

  2. Perceived Stress

    A self-report questionnaire captures whether participants perceive different life situations as overwhelming or uncontrollable. Participants will rate each question on a 5-point Likert scale, and their responses will be totaled to a stress score ranging from 0-40, with higher score indicated more perceived stress.

    Time frame: Baseline, 4, and 8 weeks

07

Study locations

1 site
  • Blood Cancer United
    Washington D.C., District of Columbia 20005, United States
08

References and documents

Individual participant data

Plan to share: No — Participant data will be shared at the aggregate, deidentified level only.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2026, 6 months after the start.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 6 months is below that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 17, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07413991
Lead sponsor
Blood Cancer United
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 1, 2026
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion